Aug 19 (Reuters) - Viking Therapeutics VKTX.O said on Tuesday its experimental weight-loss pill helped patients with obesity lose nearly 12.2% of their body weight on average over 13 weeks in a mid-stage study.
Analysts ahead of the results had expected weight loss in the range of 10% to 15% on average and greater than the 8.2% seen in a small early-stage trial.